Keith L. Crandell, MBA 

Managing Director of ARCH Venture Partners

Keith is a Co-Founder and Managing Director of ARCH Venture Partners, a 24 year-old seed and early stage venture capital partnership with offices in Chicago, Austin, San Francisco and Seattle.

Since 2004 Mr. Crandell has served as Chairman of the Advisory Board of the Illinois State Treasurer Technology Development Account, a fund-of-funds focused on Illinois private equity and venture capital partnerships. He has served as a Director of the National Venture Capital Association and the Governmental Affairs Committee. He also has been active with the IVCA since inception, recently serving as Chairman.

Prior to ARCH, Mr. Crandell worked with Hercules Inc., a specialty chemical and polymer company. He holds an M.B.A. from the University of Chicago, an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

 

Caley Castelein, MD

Managing Director of Kearny Venture Partners

Caley is a managing director of KVP. He has invested in Aspreva, Boreal, CoTherix, CVRx, Kai, Rib-X, QuatRx, and ViewRay, and is currently a board member of Boreal and ViewRay.

Prior to becoming a venture capitalist in 2000, Caley received his M.D. from the University of California, San Francisco. During medical school, he ran a research program investigating the genetic causes of deafness and the application of gene therapy to treatment of hearing loss. The findings were published in leading journals including Nature Genetics. After medical school, Caley completed a general surgery internship at the University of California, San Francisco. He received an A.B. magna cum laude from Harvard College.

 

Tom Willis, PhD, Chairman

Chief Executive Officer of Sequenta, Inc.

Prior to founding Sequenta, Tom has been an entrepreneur in the biotech industry for the past decade. After receiving his Ph.D. in physics from Stanford University, in 1996, he joined the Stanford Genome Technology Center (SGTC) to work on DNA sequence analysis technologies. He held several positions at the SGTC including Associate Director in charge of technology development. While at SGTC, Tom was the co-inventor of the Molecular Inversion Probe technology for high throughput genotyping.

In 2001, Tom co-founded ParAllele BioScience to develop and commercialize this technology. As its founding CEO, he led ParAllele through two rounds of VC financing and grew the company to over 80 employees. In 2005 ParAllele was acquired by Affymetrix at which time Tom served in several management positions at Affymetrix. He left in 2007 to pursue new startup opportunities.

 

Andre Marziali, PhD

Founder, Chief Scientific Officer

A leading innovator, educator, and entrepreneur with over 18 years’ experience in developing tools for life science research and technologies for nucleic acid analysis, Andre founded Boreal Genomics with colleagues from the University of British Columbia in 2007.

Andre received his B.A.Sc. in Engineering Physics from UBC in 1989, and his Ph.D. in Physics from Stanford University in 1994. He subsequently worked for several years with Prof. Ron Davis, in the Stanford DNA Sequencing Technology Center, developing instruments for DNA sequencing and sample purification. He returned to Canada in 1998, as an Assistant Professor at University of British Columbia in the Department of Physics and Astronomy, where he founded the Applied Biophysics Laboratory and the Genome BC Technology Development Platform. In 2005 he was appointed Director of the Engineering Physics program at UBC.

In 2004, Andre co-invented the concept of using synchronous mobility perturbations to create divergent velocity fields for selective focusing of nucleic acids, the technology which forms the basis for Boreal’s platforms. He has been awarded the 2004 BC Innovation Council – Young Innovator award, the 2007 Association for Lab Automation Innovation Award, and the 2011 Life Science BC Award for Innovation and Achievement.